Spinal Cord Stimulation and Autonomic Response in People With SCI.

NCT03924388 | Unknown

• 1 other identifier: REB18- 1592
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 2

Brief Summary

Despite being studied less than half as frequently, autonomic dysfunction is a greater priority than walking again in spinal cord injury. One autonomic condition after spinal cord injury is orthostatic hypotension, where blood pressure dramatically declines when patients assume the upright posture. Orthostatic hypotension is associated with all-cause mortality and cardiovascular incidents as well as fatigue and cognitive dysfunction, and it almost certainly contributes to an elevated risk of heart disease and stroke in people with spinal cord injury. In addition, autonomic dysfunction leads to bladder, bowel, sexual dysfunctions, which are major contributors to reduced quality and quantity of life. Unfortunately, the available options for treating this condition, are primarily limited to pharmacological options, which are not effective and are associated with various side effects. It has been recently demonstrated that spinal cord stimulation can modulate autonomic circuits and improve autonomic function in people living with spinal cord injury. Neuroanatomically, the thoracolumbar sympathetic pathways are the primary spinal cord segments involved in blood pressure control. Recently, a pilot study has been published demonstrating that transcutaneous spinal cord stimulation of thoracolumbar afferents can improve cardiovascular function. However, some studies have shown that lumbosacral transcutaneous spinal cord stimulation can also elicit positive cardiovascular effects. Therefore, there is no consensus on the optimal strategy in order to deliver transcutaneous spinal cord stimulation to improve the function of the autonomic system, and it may be that lumbosacral (i.e. the stimulation site being used most commonly for restoring leg function is sufficient). Another key knowledge gap in terms of transcutaneous spinal cord stimulation is whether or not the current is directly or indirectly activating these spinal circuits. Last but not least, the effects of epidural spinal cord stimulation on the function of cardiovascular, bladder, bowel and sexual system in spinal cord injury have been investigated in no study yet. AIMS AND HYPOTHESES: Aim 1. To examine the effects of short-term (one session) transcutaneous spinal cord stimulation on the frequency and severity of episodes of orthostatic hypotension/autonomic dysfunction, and bladder, bowel, and sexual functions. These effects will be compared at two sites of stimulation. Hypothesis 1.1: Short-term transcutaneous mid-thoracic cord stimulation will mitigate the severity and frequency of orthostatic hypotension/autonomic dysfunction. Hypothesis 1.2: Lumbosacral transcutaneous spinal cord stimulation will improve bladder, bowel, and sexual functions. Aim 2. To examine the effects of long-term (one month) transcutaneous spinal cord stimulation on the severity and frequency of orthostatic hypotension/autonomic dysfunction. Hypothesis 2.1: Long-term stimulation of the mid-thoracic cord will result in sustained improvements in mitigated severity and frequency of orthostatic hypotension/autonomic dysfunction that is not dependent on active stimulation. Hypothesis 2.2: Long-term lumbosacral transcutaneous spinal cord stimulation will result in sustained improvements in bowel, bladder, and sexual function that is not dependent on active stimulation. Aim 3: To examine the effects of short-term (one session) epidural spinal cord stimulation on the severity and frequency of orthostatic hypotension/autonomic dysfunction, and bladder, bowel, and sexual functions. Hypothesis 3.1: Epidural spinal cord stimulation will mitigate the severity and frequency of orthostatic hypotension/autonomic dysfunction and improve bladder, bowel, and sexual function. Hypothesis 3.3: There is no significant difference between immediate effects of lumbosacral transcutaneous spinal cord stimulation and epidural spinal cord stimulation on bladder, bowel, and sexual function. For aim 1, 14 participants with spinal cord injury and no implanted electrodes on the spinal cord will be recruited. Participants will randomly receive one-hour stimulation under each of the two stimulation conditions in a crossover manner: Mid-thoracic and Lumbosacral. For aim 2, 28 individuals with spinal cord injury and no implanted electrode will be pseudo-randomized (1:1) to one of two stimulation sites. Participants will receive one-hour stimulation, five sessions per week for four weeks. Cardiovascular and neurological outcomes will be measured before the first stimulation session and after the last stimulation session. For aim 3, 4 participants with spinal cord injury with implanted electrodes on the spinal cord will be recruited to study the immediate effects of invasive epidural spinal cord stimulation. All outcomes will be measured in two positions: a) Supine, b) \~ 70° upright tilt-test. Additionally, bowel, bladder, and sexual functions in project 2 will be assessed weekly.

Conditions

Spinal Cord Injuries; Autonomic Dysreflexia; Orthostatic Hypotension, Dysautonomic

Keywords

Transcutaneous Spinal Cord Stimulation; Epidural Spinal Cord Stimulation; Orthostatic Hypotension; Autonomic Dysreflexia; Spinal Cord Stimulation

Outcome Measures

Primary Outcomes (4)

• Episodic Blood Pressure Changes, the unit of measurement is mmHg

  We will monitor beat-to-beat changes of blood pressure by a Finometer. This outcome will be measured in two different positions: supine and 70 degrees upright position.

  In project 1 and 3: before stimulation and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

• Cerebral Blood Flow Changes, the unite of measurement is mililitter/(100 gram tissue minute)

  We will monitor beat-to-beat changes in blood flow by a Finometer. This outcome will be measured in two different positions: supine and 70 degrees upright position.

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

• Heart Rate Changes, the unit is beat per minute (bpm)

  We will monitor beat-to-beat changes in heart rate by electrocardiography. This outcome will be measured in two different positions: supine and 70 degrees upright position.

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

• Continues Blood Pressure Changes, the unit of measurement is mmHg

  We will monitor 24 hours of blood pressure changes by 24-hour Ambulatory Blood Pressure Monitoring.

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

Secondary Outcomes (13)

• Sympathetic Skin Responses (SSR) Changes, the unit of measurement is mV

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

• Urodynamic Study Changes

  Project 2 only: before the first stimulation session and one week, two weeks, three weeks, and four weeks after the first stimulation session.

• Electromyography (EMG) Changes

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

• American Spinal Injury Association Impairment Scale (AIS) Changes

  In project 1 and 3: before and after one hour spinal cord stimulation. Project 2: before the first stimulation session and after the last stimulation session (one month after the first stimulation session).

• Orthostatic Tilt Test Changes

  In project 1 and 3: before and after one hour spinal cord stimulation. In project 2: 24 hours before the first stimulation session and after the last stimulation session (session 21, 4 weeks after the first session).

Study Arms (3)

Short-term transcutaneous spinal cord stimulation

EXPERIMENTAL

In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function. In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and \~ 70° upright (adjusted by tilt-up table).

Device: Trnascutaneous electrical spinal cord stimulation.

Long-term transcutaneous spinal cord stimulation

EXPERIMENTAL

In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function. The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and \~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly.

Device: Trnascutaneous electrical spinal cord stimulation.

Project 3

EXPERIMENTAL

For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.

Device: Epidural spinal cord stimulation

Interventions

Epidural spinal cord stimulation DEVICE

The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.

Project 3

Trnascutaneous electrical spinal cord stimulation. DEVICE

The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.

Long-term transcutaneous spinal cord stimulation; Short-term transcutaneous spinal cord stimulation

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age limit for Project 1 and Project 2 is 18-65 years, and age limit for Project 3 is 22-65 years (Based on FDA approval, participants below 22 are not allowed undergo to implantation surgery).
• The volunteer should have \>1-year injury, at least 6 months from any spinal surgery
• Underwent electrode implantation surgery before
• Documented presence of cardiovascular dysfunction including the presence of persistent resting blood pressure and/or symptoms of AD/OH.
• Greater than or equal to antigravity strength in deltoids and biceps bilaterally.
• Participants must have documented 3 days of bladder and bowel history prior to their baseline visit.
• Willing to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).
• No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing activities.
• Stable management of spinal cord-related clinical issue (spasticity management).
• Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating.
• Sexually active males with female partners of childbearing potential must agree to effective contraception during th eperiod of the tril nad for at least 28 days after completion of treatment.
• Must provide informed consent.

You may not qualify if:

• Presence of severe acute medical issue that in the investigator's judgement would adversely affect the participant's participation in the study.
• Recent treatment with OnabotulinumtoxinA into the detrusor muscle (within 9 months of the baseline visit).
• Ventilator dependent
• Clinically significant depression or ongoing drug abuse
• Use of any medication or treatment that in the opinion of the investigator indicates that it is not the best interest of participant to participate in this study
• Indwelling baclofen pump
• Any implanted metal in the trunk or spinal cord under the sites of application of electrodes (between anode and cathode) for those who are allocated to receive NTSCS.
• Severe anemia (Hgb\<8 g/dl) or hypovolemia.
• Participant is a member of the investigational team or his /her immediate family.

Sponsors & Collaborators

• University of Calgary: lead
• International Collaboration on Repair Discoveries: collaborator

Study Sites (2)

University of Calgary

Calgary, Alberta, T2N 1N4, Canada

Location

University of British Columbia

Vancouver, British Columbia, V6T 1Z4, Canada

Location

Related Publications (55)

• Sheel AW, Krassioukov AV, Inglis JT, Elliott SL. Autonomic dysreflexia during sperm retrieval in spinal cord injury: influence of lesion level and sildenafil citrate. J Appl Physiol (1985). 2005 Jul;99(1):53-8. doi: 10.1152/japplphysiol.00154.2005. Epub 2005 Mar 24.

  PMID: 15790691 BACKGROUND

• Solinsky R, Bunnell AE, Linsenmeyer TA, Svircev JN, Engle A, Burns SP. Pharmacodynamics and effectiveness of topical nitroglycerin at lowering blood pressure during autonomic dysreflexia. Spinal Cord. 2017 Oct;55(10):911-914. doi: 10.1038/sc.2017.58. Epub 2017 Jun 6.

  PMID: 28585557 BACKGROUND

• Phillips AA, Elliott SL, Zheng MM, Krassioukov AV. Selective alpha adrenergic antagonist reduces severity of transient hypertension during sexual stimulation after spinal cord injury. J Neurotrauma. 2015 Mar 15;32(6):392-6. doi: 10.1089/neu.2014.3590. Epub 2014 Dec 5.

  PMID: 25093677 BACKGROUND

• Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996 May;46(5):1470. doi: 10.1212/wnl.46.5.1470. No abstract available.

  PMID: 8628505 BACKGROUND

• Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13. doi: 10.1161/01.str.31.10.2307.

  PMID: 11022055 BACKGROUND

• Squair JW, Phillips AA, Harmon M, Krassioukov AV. Emergency management of autonomic dysreflexia with neurologic complications. CMAJ. 2016 Oct 18;188(15):1100-1103. doi: 10.1503/cmaj.151311. Epub 2016 May 24. No abstract available.

  PMID: 27221275 BACKGROUND

• Phillips AA, Ainslie PN, Warburton DE, Krassioukov AV. Cerebral Blood Flow Responses to Autonomic Dysreflexia in Humans with Spinal Cord Injury. J Neurotrauma. 2016 Feb 1;33(3):315-8. doi: 10.1089/neu.2015.3871. Epub 2016 Jan 7.

  PMID: 26077616 BACKGROUND

• Phillips AA, Warburton DE, Ainslie PN, Krassioukov AV. Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride. J Cereb Blood Flow Metab. 2014 May;34(5):794-801. doi: 10.1038/jcbfm.2014.3. Epub 2014 Jan 29.

  PMID: 24473484 BACKGROUND

• Illman A, Stiller K, Williams M. The prevalence of orthostatic hypotension during physiotherapy treatment in patients with an acute spinal cord injury. Spinal Cord. 2000 Dec;38(12):741-7. doi: 10.1038/sj.sc.3101089.

  PMID: 11175374 BACKGROUND

• Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic Hypotension: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018 Sep 11;72(11):1294-1309. doi: 10.1016/j.jacc.2018.05.079.

  PMID: 30190008 BACKGROUND

• Mathias CJ. Orthostatic hypotension and paroxysmal hypertension in humans with high spinal cord injury. Prog Brain Res. 2006;152:231-43. doi: 10.1016/S0079-6123(05)52015-6.

  PMID: 16198704 BACKGROUND

• Sclater A, Alagiakrishnan K. Orthostatic hypotension. A primary care primer for assessment and treatment. Geriatrics. 2004 Aug;59(8):22-7.

  PMID: 15332413 BACKGROUND

• Bisharat N, Paz E, Klimov A, Friedberg N, Elias M. Cerebral syncope in a patient with spinal cord injury. Pacing Clin Electrophysiol. 2002 Mar;25(3):372-3. doi: 10.1046/j.1460-9592.2002.00372.x.

  PMID: 11990670 BACKGROUND

• Currie KD, Krassioukov AV. A walking disaster: a case of incomplete spinal cord injury with symptomatic orthostatic hypotension. Clin Auton Res. 2015 Oct;25(5):335-7. doi: 10.1007/s10286-015-0309-7. Epub 2015 Aug 12.

  PMID: 26264838 BACKGROUND

• Claydon VE, Krassioukov AV. Orthostatic hypotension and autonomic pathways after spinal cord injury. J Neurotrauma. 2006 Dec;23(12):1713-25. doi: 10.1089/neu.2006.23.1713.

  PMID: 17184183 BACKGROUND

• Sidorov EV, Townson AF, Dvorak MF, Kwon BK, Steeves J, Krassioukov A. Orthostatic hypotension in the first month following acute spinal cord injury. Spinal Cord. 2008 Jan;46(1):65-9. doi: 10.1038/sj.sc.3102064. Epub 2007 Apr 10.

  PMID: 17420772 BACKGROUND

• Carlozzi NE, Fyffe D, Morin KG, Byrne R, Tulsky DS, Victorson D, Lai JS, Wecht JM. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch Phys Med Rehabil. 2013 Sep;94(9):1721-30. doi: 10.1016/j.apmr.2013.02.024. Epub 2013 Mar 14.

  PMID: 23499779 BACKGROUND

• West CR, Krassioukov AV. Autonomic cardiovascular control and sports classification in Paralympic athletes with spinal cord injury. Disabil Rehabil. 2017 Jan;39(2):127-134. doi: 10.3109/09638288.2015.1118161. Epub 2016 Jan 5.

  PMID: 26729004 BACKGROUND

• Phillips AA, Squair JW, Krassioukov AV. Paralympic Medicine: The Road to Rio. J Neurotrauma. 2017 Jun 1;34(11):2001-2005. doi: 10.1089/neu.2016.4715. Epub 2017 Jan 24.

  PMID: 27998237 BACKGROUND

• Harris P. Self-induced autonomic dysreflexia ('boosting') practised by some tetraplegic athletes to enhance their athletic performance. Paraplegia. 1994 May;32(5):289-91. doi: 10.1038/sc.1994.50. No abstract available.

  PMID: 8058344 BACKGROUND

• Gee CM, West CR, Krassioukov AV. Boosting in Elite Athletes with Spinal Cord Injury: A Critical Review of Physiology and Testing Procedures. Sports Med. 2015 Aug;45(8):1133-42. doi: 10.1007/s40279-015-0340-9.

  PMID: 26009300 BACKGROUND

• Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil. 2010 Sep;91(9):1429-35. doi: 10.1016/j.apmr.2010.06.017.

  PMID: 20801263 BACKGROUND

• Wu JC, Chen YC, Liu L, Chen TJ, Huang WC, Cheng H, Tung-Ping S. Increased risk of stroke after spinal cord injury: a nationwide 4-year follow-up cohort study. Neurology. 2012 Apr 3;78(14):1051-7. doi: 10.1212/WNL.0b013e31824e8eaa. Epub 2012 Feb 29.

  PMID: 22377807 BACKGROUND

• Bell EJ, Agarwal SK, Cushman M, Heckbert SR, Lutsey PL, Folsom AR. Orthostatic Hypotension and Risk of Venous Thromboembolism in 2 Cohort Studies. Am J Hypertens. 2016 May;29(5):634-40. doi: 10.1093/ajh/hpv151. Epub 2015 Aug 25.

  PMID: 26306405 BACKGROUND

• Agarwal SK, Alonso A, Whelton SP, Soliman EZ, Rose KM, Chamberlain AM, Simpson RJ Jr, Coresh J, Heiss G. Orthostatic change in blood pressure and incidence of atrial fibrillation: results from a bi-ethnic population based study. PLoS One. 2013 Nov 11;8(11):e79030. doi: 10.1371/journal.pone.0079030. eCollection 2013.

  PMID: 24244409 BACKGROUND

• Squair JW, DeVeau KM, Harman KA, Poormasjedi-Meibod MS, Hayes B, Liu J, Magnuson DSK, Krassioukov AV, West CR. Spinal Cord Injury Causes Systolic Dysfunction and Cardiomyocyte Atrophy. J Neurotrauma. 2018 Feb 1;35(3):424-434. doi: 10.1089/neu.2017.4984. Epub 2017 Oct 13.

  PMID: 28599602 BACKGROUND

• Woodbury MG, Hayes KC, Askes HK. Intermittent catheterization practices following spinal cord injury: a national survey. Can J Urol. 2008 Jun;15(3):4065-71.

  PMID: 18570710 BACKGROUND

• Liu N, Fougere R, Zhou MW, Nigro MK, Krassioukov AV. Autonomic dysreflexia severity during urodynamics and cystoscopy in individuals with spinal cord injury. Spinal Cord. 2013 Nov;51(11):863-7. doi: 10.1038/sc.2013.113. Epub 2013 Sep 24.

  PMID: 24060768 BACKGROUND

• Teasell RW, Arnold JM, Krassioukov A, Delaney GA. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med Rehabil. 2000 Apr;81(4):506-16. doi: 10.1053/mr.2000.3848.

  PMID: 10768544 BACKGROUND

• Ho CP, Krassioukov AV. Autonomic dysreflexia and myocardial ischemia. Spinal Cord. 2010 Sep;48(9):714-5. doi: 10.1038/sc.2010.2. Epub 2010 Feb 2.

  PMID: 20125109 BACKGROUND

• Eltorai I, Kim R, Vulpe M, Kasravi H, Ho W. Fatal cerebral hemorrhage due to autonomic dysreflexia in a tetraplegic patient: case report and review. Paraplegia. 1992 May;30(5):355-60. doi: 10.1038/sc.1992.82.

  PMID: 1598177 BACKGROUND

• Wan D, Krassioukov AV. Life-threatening outcomes associated with autonomic dysreflexia: a clinical review. J Spinal Cord Med. 2014 Jan;37(1):2-10. doi: 10.1179/2045772313Y.0000000098. Epub 2013 Nov 26.

  PMID: 24090418 BACKGROUND

• Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol. 2013 Jun 15;304(12):H1598-614. doi: 10.1152/ajpheart.00490.2012. Epub 2013 Apr 12.

  PMID: 23585139 BACKGROUND

• Zheng MM, Phillips AA, Elliott SL, Krassioukov AV. Prazosin: a potential new management tool for iatrogenic autonomic dysreflexia in individuals with spinal cord injury? Neural Regen Res. 2015 Apr;10(4):557-8. doi: 10.4103/1673-5374.155422. No abstract available.

  PMID: 26170812 BACKGROUND

• Krassioukov A, Warburton DE, Teasell R, Eng JJ; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009 Apr;90(4):682-95. doi: 10.1016/j.apmr.2008.10.017.

  PMID: 19345787 BACKGROUND

• Claydon VE, Steeves JD, Krassioukov A. Orthostatic hypotension following spinal cord injury: understanding clinical pathophysiology. Spinal Cord. 2006 Jun;44(6):341-51. doi: 10.1038/sj.sc.3101855. Epub 2005 Nov 22.

  PMID: 16304564 BACKGROUND

• Krassioukov A, Eng JJ, Warburton DE, Teasell R; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of orthostatic hypotension after spinal cord injury. Arch Phys Med Rehabil. 2009 May;90(5):876-85. doi: 10.1016/j.apmr.2009.01.009.

  PMID: 19406310 BACKGROUND

• Hofstoetter US, Freundl B, Binder H, Minassian K. Common neural structures activated by epidural and transcutaneous lumbar spinal cord stimulation: Elicitation of posterior root-muscle reflexes. PLoS One. 2018 Jan 30;13(1):e0192013. doi: 10.1371/journal.pone.0192013. eCollection 2018.

  PMID: 29381748 BACKGROUND

• West CR, Phillips AA, Squair JW, Williams AM, Walter M, Lam T, Krassioukov AV. Association of Epidural Stimulation With Cardiovascular Function in an Individual With Spinal Cord Injury. JAMA Neurol. 2018 May 1;75(5):630-632. doi: 10.1001/jamaneurol.2017.5055.

  PMID: 29459943 BACKGROUND

• Aslan SC, Legg Ditterline BE, Park MC, Angeli CA, Rejc E, Chen Y, Ovechkin AV, Krassioukov A, Harkema SJ. Epidural Spinal Cord Stimulation of Lumbosacral Networks Modulates Arterial Blood Pressure in Individuals With Spinal Cord Injury-Induced Cardiovascular Deficits. Front Physiol. 2018 May 18;9:565. doi: 10.3389/fphys.2018.00565. eCollection 2018.

  PMID: 29867586 BACKGROUND

• Phillips AA, Squair JW, Sayenko DG, Edgerton VR, Gerasimenko Y, Krassioukov AV. An Autonomic Neuroprosthesis: Noninvasive Electrical Spinal Cord Stimulation Restores Autonomic Cardiovascular Function in Individuals with Spinal Cord Injury. J Neurotrauma. 2018 Feb 1;35(3):446-451. doi: 10.1089/neu.2017.5082. Epub 2017 Nov 21.

  PMID: 28967294 BACKGROUND

• Wecht JM, Bauman WA. Implication of altered autonomic control for orthostatic tolerance in SCI. Auton Neurosci. 2018 Jan;209:51-58. doi: 10.1016/j.autneu.2017.04.004. Epub 2017 May 3.

  PMID: 28499865 BACKGROUND

• Biering-Sorensen F, Craggs M, Kennelly M, Schick E, Wyndaele JJ. International lower urinary tract function basic spinal cord injury data set. Spinal Cord. 2008 May;46(5):325-30. doi: 10.1038/sj.sc.3102145. Epub 2007 Nov 27.

  PMID: 18040278 BACKGROUND

• Fougere RJ, Currie KD, Nigro MK, Stothers L, Rapoport D, Krassioukov AV. Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. J Neurotrauma. 2016 Sep 15;33(18):1651-7. doi: 10.1089/neu.2015.4278. Epub 2016 Apr 13.

  PMID: 26980078 BACKGROUND

• Prevention of thromboembolism in spinal cord injury. Consortium for Spinal Cord Medicine. J Spinal Cord Med. 1997 Jul;20(3):259-83. doi: 10.1080/10790268.1997.11719479. No abstract available.

  PMID: 9261774 BACKGROUND

• Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, Jones L, Krassioukov A, Mulcahey MJ, Schmidt-Read M, Waring W. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011 Nov;34(6):535-46. doi: 10.1179/204577211X13207446293695. No abstract available.

  PMID: 22330108 BACKGROUND

• Laughlin MH, Schrage WG. Effects of muscle contraction on skeletal muscle blood flow: when is there a muscle pump? Med Sci Sports Exerc. 1999 Jul;31(7):1027-35. doi: 10.1097/00005768-199907000-00016.

  PMID: 10416565 BACKGROUND

• Hubli M, Currie KD, West CR, Gee CM, Krassioukov AV. Physical exercise improves arterial stiffness after spinal cord injury. J Spinal Cord Med. 2014 Nov;37(6):782-5. doi: 10.1179/2045772314Y.0000000232. Epub 2014 Jun 29.

  PMID: 24976366 BACKGROUND

• Hubli M, Krassioukov AV. Ambulatory blood pressure monitoring in spinal cord injury: clinical practicability. J Neurotrauma. 2014 May 1;31(9):789-97. doi: 10.1089/neu.2013.3148. Epub 2014 Jan 30.

  PMID: 24175653 BACKGROUND

• Contributors:; Krassioukov A, Biering-Sorensen CF, Donovan W, Kennelly M, Kirshblum S, Krogh K, Alexander MS, Vogel L, And Wecht J. International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI), First Edition 2012. Top Spinal Cord Inj Rehabil. 2012 Summer;18(3):282-96. doi: 10.1310/sci1803-282. No abstract available.

  PMID: 23460763 BACKGROUND

• West CR, Gee CM, Voss C, Hubli M, Currie KD, Schmid J, Krassioukov AV. Cardiovascular control, autonomic function, and elite endurance performance in spinal cord injury. Scand J Med Sci Sports. 2015 Aug;25(4):476-85. doi: 10.1111/sms.12308. Epub 2014 Aug 31.

  PMID: 25175825 BACKGROUND

• Costa P, Perrouin-Verbe B, Colvez A, Didier J, Marquis P, Marrel A, Amarenco G, Espirac B, Leriche A. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol. 2001 Jan;39(1):107-13. doi: 10.1159/000052421.

  PMID: 11173948 BACKGROUND

• Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.

  PMID: 15817019 BACKGROUND

• Malhotra A, Shah N, Depasquale J, Baddoura W, Spira R, Rector T. Use of Bristol Stool Form Scale to predict the adequacy of bowel preparation - a prospective study. Colorectal Dis. 2016 Feb;18(2):200-4. doi: 10.1111/codi.13084.

  PMID: 26268220 BACKGROUND

• Krogh K, Christensen P, Sabroe S, Laurberg S. Neurogenic bowel dysfunction score. Spinal Cord. 2006 Oct;44(10):625-31. doi: 10.1038/sj.sc.3101887. Epub 2005 Dec 13.

  PMID: 16344850 BACKGROUND

MeSH Terms

Conditions

Spinal Cord Injuries; Autonomic Dysreflexia; Shy-Drager Syndrome; Hypotension, Orthostatic

Condition Hierarchy (Ancestors)

Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System; Wounds and Injuries; Autonomic Nervous System Diseases; Multiple System Atrophy; Primary Dysautonomias; Basal Ganglia Diseases; Brain Diseases; Movement Disorders; Hypotension; Vascular Diseases; Cardiovascular Diseases; Orthostatic Intolerance

Central Study Contacts

Aaron Phillips, PhD (Medicine)

CONTACT

(+1) 403-220-5672; aaron.phillips@ucalgary.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor, Physiology & Pharmacology, Cardiac Sciences and Clinical Neurosciences

Model Details: Project 1 and 2: This multi-site open-label exploratory clinical trial (phase IIb) on examination of the effects of non-invasive transcutaneous spinal cord stimulation will take place at University of Calgary and the University of British Clombia, Canada. In a pseudo-randomized controlled 2×2 between-subject factorial design. Project 3: This is a multi-site open-label case study exploring the effects of invasive epidural spinal cord stimulation on small number of individuals with SCI who underwent epidural implantation in Canada or abroad.

Study Record Dates

• First Submitted: March 21, 2019
• First Posted: April 23, 2019
• Study Start: February 1, 2020
• Primary Completion: December 1, 2021
• Study Completion: March 1, 2022
• Last Updated: December 17, 2019

Record last verified: 2019-12

Locations

CA (2)